Abingworth Management, of London, appointed Sarah Shackelton to expand the venture capital group's relationships and to assist portfolio companies with their recruitment needs.
Acacia Research Corp., of Newport Beach, Calif., appointed Mark Kay to its scientific advisory board.
Adolor Corp., of Exton, Pa., appointed John Fort vice president of medical affairs, and promoted Denise Kerton to vice president human resources and David Christ to vice president preclinical development.
Allylix Inc., of Louisville, Ky., appointed Terry Minton CEO.
Altus Biologics Inc., of Cambridge, Mass., appointed Lynne Brum to its board.
BioRexis Pharmaceutical Corp., of King of Prussia, Pa., appointed Vanaja Ragavan vice president of clinical and regulatory affairs.
Conforma Therapeutics Corp., of San Diego, appointed Christopher LeMasters vice president of corporate development.
Corgentech Inc., of South San Francisco, appointed Richard Brewer to its board.
Cylene Pharmaceuticals Inc., of San Diego, appointed John Lim vice president of clinical operations.
DW Healthcare Partners, of Salt Lake City, appointed Barrie Keiser managing director.
NsGene A/S, of Copenhagen, Denmark, appointed Soren Mouritsen to its board.
Piper Jaffray & Co., of New York, appointed Mark Karvosky vice president and senior biotechnology research analyst.
The Pittsburgh Life Sciences Greenhouse appointed Grainne McClorey executive assistant, and promoted David Palmer to chief operating officer, Reed McManigle to director of investment programs and incubation services and Pamela Bush to investment programs manager.
RBC Capital Markets, of New York, appointed John Patterson managing director in the health care services group in New York, Andy Singer vice president in the life sciences group in San Francisco, Dave Bouchey vice president in the biotechnology research group in Denver and Ken Trbovich vice president in the specialty pharma research group in Denver.
Stryker Corp., of Kalamazoo, Mich., appointed Mark Philip president of Stryker Biotech, which is focused on commercializing the bone growth factor osteogenic protein-1 (OP-1).
Tissera Inc., of Tel Aviv, Israel, appointed Yair Reisner chairman of the scientific advisory board.
Trubion Pharmaceuticals Inc., of Seattle, appointed Daniel Burge senior vice president of clinical development.
VaxGen Inc., of Brisbane, Calif., appointed James Cunha interim chief financial officer.
ViroPharma Inc., of Exton, Pa., appointed William Roberts director of corporate communications.